Back to search

Article

HMPL-306 (Ranosidenib): The Next Frontier in mIDH Cancer Therapy

2025-03-15

Abstract excerpt

Abstract HMPL-306 (Ranosidenib), a novel dual inhibitor of mutant isocitrate dehydrogenase 1 and 2 (mIDH1/2), emerges as a transformative therapeutic strategy for cancers harboring mIDH mutations, addressing critical limitations of single-target therapies. By concurrently inhibiting mIDH1/2, HMPL-306 circumvents isoform switching, a key resistance mechanism and potently suppresses the oncometabolite 2-hydroxygluta...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
2b289d17-3283-565e-a4ca-49529d0caeaa
DOI
10.22541/au.174202403.31267308/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
HMPL-306 (Ranosidenib): The Next Frontier in mIDH Cancer TherapyDOI 10.22541/au.174202403.31267308/v1
Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer TherapeuticsSemantic proximity
Therapeutic inhibition of isocitrate dehydrogenase mutations in glioma and cholangiocarcinoma: new insights and promises-a narrative review.Semantic proximity
Isocitrate Dehydrogenase Mutant Grade II and III Glial Neoplasms.Semantic proximity
Ivosidenib: First Global ApprovalSemantic proximity
Isocitrate Dehydrogenase Mutation and (R)-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development.Semantic proximity
Therapies for IDH-Mutant Gliomas.Semantic proximity
Recent advances of IDH1 mutant inhibitor in cancer therapySemantic proximity
Discovery of Novel Dual Inhibitors Targeting Mutant IDH1 and NAMPT for the Treatment of Glioma with IDH1Mutation.Semantic proximity
Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial.Semantic proximity
Targeting Isocitrate Dehydrogenase (IDH) in Solid Tumors: Current Evidence and Future PerspectivesSemantic proximity
Inhibition of 2-Hydroxyglutrate Elicits Metabolic-reprograming and Mutant IDH1 Glioma ImmunitySemantic proximity
Bridging Cancer Biology with the Clinic: Comprehending and Exploiting IDH Gene Mutations in Gliomas.Semantic proximity
Select a neighboring publication to make it the new centre.